Massive Bio will partner with non-profit group Veterans Prostate Cancer Awareness (VPCa) and patient-centered organization Self-Care Catalysts to promote enrollment in clinical trials and in real world evidence (RWE) studies. Massive Bio provides extensive experience in clinical trial enrollment […]
JMCP Article Details Payer Perceptions of Oncology RWD During Drug Launches
In a recent article published in the Journal of Managed Care and Specialty Pharmacy (JMCP), the authors discuss the use of real world data (RWD) by payers. The study explores how RWD and real world evidence (RWE) impact payer decision-making. According to the results of a survey of 221 payers, […]
Aduhelm Approval Prompts Discussions on Reforming the FDA’s Accelerated Approval Pathway
The Food and Drug Administration (FDA)’s contentious approval of Biogen’s Aduhelm has prompted discussions on how the accelerated approval process could be reformed. The FDA’s Rick Pazdur expressed concern while a recent article co-authored by the Institute for Clinical and Economic Review (ICER)’s […]
xCures VP Discusses Leveraging RWD Registries to Provide Personalized Care to Oncology Patients
Vice President of Research Partnerships at xCures Max Goldstein discusses using real world data (RWD) to better understand which patients will respond to cancer treatments. Despite extensive data from randomized controlled trials, knowing how a patient will respond to a given therapy remains a […]
Researchers Evaluate Oncology Treatment Costs at the National Cancer Institute and Community Hospitals
Researchers evaluated costs associated with cancer treatment in community hospitals and at the National Cancer Insitute (NCI), noting variation in costs despite no changes in care utilization between the two types of locations. “The study is believed to be the first to report on variations in […]
Register Today for IQVIA’s Tuesday Webinar on Surrogate Endpoints in Oncology Clinical Trials
The IQVIA Institute for Human Data Science will host a webinar at 10:00 AM EDT on Tuesday, August 17th on surrogate endpoints used in oncology clinical trials. Panelists will discuss the perspectives of payers, providers, and how surrogate endpoints are impacting reimbursement […]
Upcoming ISPOR Webinar on Successfully Incorporating External Controls Into Oncology RWE Studies
The International Society for Pharmacoeconomics and Outcomes (ISPOR) will host a webinar on August 12th at 2:00 PM EDT on successfully using external controls in oncology real world evidence (RWE) studies. A diverse group of speakers including statisticians, clinicians, and RWE experts will discuss […]
JMCP Article Discusses Payer Viewpoints Regarding RWE, Notes Widespread Use of Claims Data
An article published in the Journal Of Managed Care and Specialty Pharmacy discusses how real world evidence (RWE) can inform healthcare decision-making and bolster randomized controlled trials. Researchers conducted a survey of payers in the United States with the goal of understanding how payers […]
Study Highlights Use of RWD and Data Analytics to Identify High-Risk Prostate Cancer Patients
Researchers at the University of Michigan used real world data (RWD) and data analytics to determine which prostate cancer patients faced a higher risk of aggressive prostate cancer, therefore requiring earlier clinical interventions. The researchers found success in their approach, noting that this […]
New ISPOR Article Highlights Need for Clearly Defining Fit-For-Purpose RWD in Oncology Research, Reveals UReQA RWD Selection Framework
Fit-for-purpose real world data (RWD) is an attractive source of decision-making data. Multiple stakeholders, including regulatory affairs professionals and payers, have increasingly turned to such data. However, a lack of consensus surrounding the term leads to confusion and uncertainty, according […]
